We are live on ! Find out more
NVS icon

Novartis

150.47 USD
-0.75
0.5%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
150.00
-0.47
0.31%
1 day
-0.5%
5 days
-7.32%
1 month
-2.06%
3 months
-3.69%
6 months
0.01%
Year to date
8.61%
1 year
21%
5 years
85.03%
10 years
139.45%
 

About: Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Employees: 75,267

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 39.7%
Neutral 21.6%
Negative 38.8%
Positive
MarketBeat
1 day ago
Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom
Novartis NYSE: NVS executives outlined a slate of upcoming drug-trial results and regulatory discussions across immunology, cardiovascular disease, oncology and neuroscience, while reiterating sales ambitions for several established medicines.
Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom
Positive
MarketBeat
1 day ago
Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven
Novartis NYSE: NVS is applying artificial intelligence across drug research and clinical development, with executives reporting faster trial enrollment and drug candidate selection while cautioning that evidence of improved clinical success will take longer to emerge.
Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven
Neutral
CNBC Television
1 day ago
Novartis CEO Vas Narasimhan on Anthropic IPO: I'm incredibly proud, and it's a very exciting day
Vas Narasimhan, Novartis CEO and Anthropic Board of Directors member, joins 'Squawk on the Street' to discuss Anthropic's historic IPO, safety risks around new AI models, upside risk, and more.
Novartis CEO Vas Narasimhan on Anthropic IPO: I'm incredibly proud, and it's a very exciting day
Positive
24/7 Wall Street
1 day ago
3 Big Pharma Dividend Stocks Built for Retirement Income
Three drugmakers promise retirees steady paychecks, yet one faces a looming Eliquis cliff and two pay in foreign currencies that can shrink the check. Which dividend is safest when earnings look shaky but cash tells a different story?
3 Big Pharma Dividend Stocks Built for Retirement Income
Positive
MarketBeat
1 day ago
Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations
Novartis NYSE: NVS expects annual sales growth of 5% from 2026 through 2031 and average mid-single-digit growth into the mid-2030s, as the drugmaker looks to offset patent expirations with newer medicines and its development pipeline.
Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations
Neutral
Seeking Alpha
2 days ago
Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline Transcript
Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline Transcript
Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline Transcript
Negative
Reuters
2 days ago
Novartis trims medium-term growth target, shares fall
Swiss drugmaker Novartis is targeting annual sales growth of 5% through 2031, the lower end of ‌its previous five-year guidance, as looming patent expiries and a series of late-stage trial setbacks increase pressure on its blockbuster drugs.
Novartis trims medium-term growth target, shares fall
Positive
CNBC
2 days ago
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
Ahead of its Capital Markets Day on Thursday, Novartis upgraded its peak sales outlook for three of its blockbuster drugs to a combined $18 billion, up from a previous forecast of a combined $14 billion The company projected annual sales growth of 5% through 2031, slightly less ambitious than its previous guidance of 5% to 6% through 2030.
Novartis bets on bigger blockbusters to power growth, forecasting 5% annual sales through 2031
Positive
WSJ
2 days ago
Novartis Sees Sales Growth Through 2031
The drugmaker expects annual sales growth of 5% from 2026 to 2031, from a previous forecast of 5% to 6% over the 2025-30 period.
Novartis Sees Sales Growth Through 2031
Positive
Reuters
2 days ago
Novartis targets 5% annual sales growth through 2031
Swiss drugmaker Novartis ​set a target of annual sales growth of 5% through 2031 on Thursday, relying on a handful of drugs already on the market to offset looming patent expiries and recover from a string of late-stage trial setbacks.
Novartis targets 5% annual sales growth through 2031
Price charts implemented using Lightweight Charts™